Health Care & Life Sciences » Biotechnology | biOasis Technologies Inc.

biOasis Technologies Inc.

biOasis Technologies Inc.
Stock Exchange Other OTC
EPS
$0.04
Market Cap
$13.33 M
Shares Outstanding
58.59 M
Public Float
45.4 M
biOasis Technologies Inc.
Stock Exchange Toronto Ventures Stock Exchange
EPS
CAD0.06
Market Cap
CAD17.06 M
Shares Outstanding
45.65 M
Public Float
39.73 M

Profile

Address
14 Water Street
Guilford Connecticut 06437
United States
Employees -
Website http://www.bioasis.ca
Updated 07/08/2019
biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Rob Hutchison on May 3, 2007 and is headquartered in Vancouver, Canada.

Financials

View All
Created with Highcharts 5.0.14biOasis Technologies Inc.Net Income. Fiscal year is March-February. All values CAD Thousands.3 6103 6102 8362 8362 5722 5722 9902 9905 3075 3073 4733 47320142015201620172018201901k2k3k4k5k6k
Created with Highcharts 5.0.14biOasis Technologies Inc.Sales/Revenue. Fiscal year is March-February. All values CAD Thousands.00003693695135135895891 4221 4222014201520162017201820190250500750100012501500

Deborah Rathjen
Chairman
Mark Day
President, Chief Executive Officer & Director